Developer docs
API playgroundTry for free, no card

Search company profiles

TF Capital

Full company profile

uuid0008bik

Namestring
TF Capital
Legal namestring
TF Capital
Websiteurl
tfcapital.net
Company typeenum
Private
Founded yearint
2014
Descriptiontext

TF Capital (泰福资本) is a Shanghai-headquartered, dual-currency venture capital firm founded in 2014 that specializes in early-stage biotechnology and pharmaceutical investments in China. The firm operates as the "first and most significant money" investor for innovative biotech companies, providing capital alongside strategic expertise and leveraging proprietary deal sourcing through deep biopharmaceutical industrial networks and exclusive founder relationships. TF Capital invests across oncology, immunology, neuroscience, metabolic diseases, ophthalmology, and emerging modalities including RNA-targeting therapeutics, with a portfolio spanning 100+ companies and 20+ realized IPOs across NASDAQ, the Hong Kong Stock Exchange, the ChiNext Board, and the STAR Market.

The firm is led by two partners: K. Chiang (Founding & Managing Partner, Wharton MBA, with 30+ years of VC experience from Morningside Family Office and A.T. Kearney) and Wei Cheng (Partner, Ph.D. from the University of Massachusetts Medical School, with 20+ years of biomedical R&D, BD, and investment experience). TF Capital's primary customer segments are early-stage biotech innovators (which receive capital, strategic support, and global partnership facilitation) and institutional fund investors/LPs (which provide fund capital). Revenue is generated through portfolio company exits — including IPOs and license-out transactions — and management fees on its disclosed $1B in AUM.

TF Capital's most distinguishing outcome is its dominance in China's cross-border biotech license-out market: across 2019–2023, portfolio companies generated $2.8B+ in upfronts from 25 deals with multinational pharmaceutical corporations; in 2023 TF Capital captured 5 of the Top 15 highest upfront payments in Chinese innovator drug license-outs; and in 2024, portfolio license-out upfronts accounted for 38% of China's total ($4.1B), including the Regor→Genentech ($850M), LaNova→MSD ($588M), and Cellular Biomedicine→J&J ($245M) transactions. The firm's headquarters is located at Unit 801, CPIC XINTIANDI TOWER 2, 288 Xizang Road (S), Shanghai, China.

Short descriptiontext

TF Capital (泰福资本) is a Shanghai-based, dual-currency venture capital firm specializing in early-stage biotech investments in China, managing $1B AUM across 100+ portfolio companies with 20+ IPOs and a dominant share of China's biotech license-out market.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersShanghai, China
HQ citystring
Shanghai
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biotech venture capital, early-stage pharma investing, license-out deal sourcing, biopharmaceutical investment, life sciences portfolio management
Industry1 code
PRIMARYFSANAHAN
Corporate Strategic Real Assets & Infrastructure Venture Investing
NAICS code1 code
  • Securities, Commodity Contracts, and Other Financial Investments and Related Activities523
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital — Early-Stage Biotech
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Investment Returns and Management Fees
TypeLicensing Royalties
Description

VC firm generates returns through capital appreciation of portfolio companies, exits via IPOs and M&A, and collects management fees from fund investors.

tfcapital.net
Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

TF Capital is a Shanghai-based dual-currency venture capital firm that invests in early-stage innovative biotech and pharmaceutical companies in China. It provides capital and full value-chain strategic support to portfolio companies from inception through IPO, leveraging proprietary deal sourcing and deep biopharmaceutical networks. The firm has built a portfolio of 100+ companies and generated over $2.8B in upfront payments from license-out deals with multinational corporations.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • $2.8B+ in upfronts generated from 25 license-out deals across 14 companies in 5 consecutive years with MNCs
+5 more records
Product overview1 text field

TF Capital is a dual-currency venture capital firm specializing in early-stage biotech investment. Founded in Shanghai in 2014, the firm provides capital and strategic expertise to innovative biotech companies from inception to global impact. The firm does not offer discrete technology products or services; rather, it delivers investment products including proprietary deal sourcing, strategic partnership facilitation with listed companies, clinical experts, and investment funds, and full value-chain support for portfolio companies through to IPO and exit.

Product and service1 record
1TF Capital Early-Stage Biotech Venture Fund
CategoryVenture Capital Fund
Description

Dual-currency venture capital fund providing capital and full value-chain strategic support to early-stage biotech and pharmaceutical companies in China. Available to limited partners (institutional investors) as a committed-capital fund vehicle; deployed into portfolio companies as venture financing. Manages approximately $1B AUM and has invested in 100+ companies with 20+ IPOs achieved.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

US-based early-stage biotech VC with a long track record of founding and exiting life sciences companies. Comparable in early-stage biotech sourcing and university/founder-relationship-driven model.

TypeDirect peer
Description

China-focused asset manager with a dedicated biotech/healthcare investment platform and active license-out pipeline. Directly comparable in mandate, scale and China healthcare focus.

TypeDirect peer
Description

Leading Shanghai-based VC with deep healthcare and biotech franchise. Co-led Vivatides' $54M Series A in which TF Capital participated, indicating directly overlapping deal flow and LP/market positioning.

TypeDirect peer
Description

Healthcare and biotech-dedicated China investor that participated in Vivatides' Series A alongside TF Capital, signaling directly overlapping deal sourcing and similar China biotech VC mandate.

TypeBroad incumbent
Description

Major China-rooted investment platform with material healthcare/biotech exposure across public and private markets. Comparable as a scaled incumbent in China biotech investing, though much broader in mandate.

TypeDirect peer
Description

Global healthcare-dedicated investment firm with early-stage biotech activity, including exposure to China. Closely comparable in early-stage biotech focus and pharma partnership-driven exit model.

7Legend Capital
TypeDirect peer
Description

Established China-focused VC with significant biotech investments; TF Capital partner Wei Cheng previously held senior roles at affiliated Tsinghua Holdings Capital/LegendStar, indicating a closely comparable franchise with overlapping networks.

TypeDirect peer
Description

China healthcare/biotech-focused investor and existing backer of Vivatides Therapeutics alongside TF Capital. Directly comparable as a co-investor in the same early-stage China biotech rounds.

TypeDirect peer
Description

US-based early-stage biotech-focused VC that builds companies from inception with a strong pharma partnership exit model. Comparable in biotech-only mandate and pharma BD-driven value creation.

TypeBroad incumbent
Description

One of the largest China-focused VCs with active healthcare/biotech investing and global exit capabilities. Comparable incumbent competitor for biotech founders, though broader in sector coverage.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment61 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

TF Capital

Venture Capital — Early-Stage Biotechtfcapital.net

TF Capital (泰福资本) is a Shanghai-based, dual-currency venture capital firm specializing in early-stage biotech investments in China, managing $1B AUM across 100+ portfolio companies with 20+ IPOs and a dominant share of China's biotech license-out market.

What TF Capital does

TF Capital (泰福资本) is a Shanghai-headquartered, dual-currency venture capital firm founded in 2014 that specializes in early-stage biotechnology and pharmaceutical investments in China. The firm operates as the "first and most significant money" investor for innovative biotech companies, providing capital alongside strategic expertise and leveraging proprietary deal sourcing through deep biopharmaceutical industrial networks and exclusive founder relationships. TF Capital invests across oncology, immunology, neuroscience, metabolic diseases, ophthalmology, and emerging modalities including RNA-targeting therapeutics, with a portfolio spanning 100+ companies and 20+ realized IPOs across NASDAQ, the Hong Kong Stock Exchange, the ChiNext Board, and the STAR Market.

The firm is led by two partners: K. Chiang (Founding & Managing Partner, Wharton MBA, with 30+ years of VC experience from Morningside Family Office and A.T. Kearney) and Wei Cheng (Partner, Ph.D. from the University of Massachusetts Medical School, with 20+ years of biomedical R&D, BD, and investment experience). TF Capital's primary customer segments are early-stage biotech innovators (which receive capital, strategic support, and global partnership facilitation) and institutional fund investors/LPs (which provide fund capital). Revenue is generated through portfolio company exits — including IPOs and license-out transactions — and management fees on its disclosed $1B in AUM.

TF Capital's most distinguishing outcome is its dominance in China's cross-border biotech license-out market: across 2019–2023, portfolio companies generated $2.8B+ in upfronts from 25 deals with multinational pharmaceutical corporations; in 2023 TF Capital captured 5 of the Top 15 highest upfront payments in Chinese innovator drug license-outs; and in 2024, portfolio license-out upfronts accounted for 38% of China's total ($4.1B), including the Regor→Genentech ($850M), LaNova→MSD ($588M), and Cellular Biomedicine→J&J ($245M) transactions. The firm's headquarters is located at Unit 801, CPIC XINTIANDI TOWER 2, 288 Xizang Road (S), Shanghai, China.

TF Capital firmographics

Firmographics
Name
TF Capital
Legal name
TF Capital
Website
https://tfcapital.net
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
TF Capital (泰福资本) is a Shanghai-based, dual-currency venture capital firm specializing in early-stage biotech investments in China, managing $1B AUM across 100+ portfolio companies with 20+ IPOs and a dominant share of China's biotech license-out market.
Ownership category
akta.pro rank

TF Capital industry classification

Industry
Product category
Venture Capital — Early-Stage Biotech
NAICS
Securities, Commodity Contracts, and Other Financial Investments and Related Activities (523)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAHAN
Corporate Strategic Real Assets & Infrastructure Venture Investing

Keywords

  • Biotech venture capital
  • Early-stage pharma investing
  • License-out deal sourcing
  • Biopharmaceutical investment
  • Life sciences portfolio management

Where TF Capital is headquartered

Location

Headquarters

HQ city
Shanghai
HQ country
China
HQ region
Asia

Offices1 record

Markets served

TF Capital business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Investment Returns and Management Fees: VC firm generates returns through capital appreciation of portfolio companies, exits via IPOs and M&A, and collects management fees from fund investors.

Go-to-market motion1 record

Distribution channels2 records

TF Capital product offering

Product offering

Core offering

TF Capital is a Shanghai-based dual-currency venture capital firm that invests in early-stage innovative biotech and pharmaceutical companies in China. It provides capital and full value-chain strategic support to portfolio companies from inception through IPO, leveraging proprietary deal sourcing and deep biopharmaceutical networks. The firm has built a portfolio of 100+ companies and generated over $2.8B in upfront payments from license-out deals with multinational corporations.

Product overview

TF Capital is a dual-currency venture capital firm specializing in early-stage biotech investment. Founded in Shanghai in 2014, the firm provides capital and strategic expertise to innovative biotech companies from inception to global impact. The firm does not offer discrete technology products or services; rather, it delivers investment products including proprietary deal sourcing, strategic partnership facilitation with listed companies, clinical experts, and investment funds, and full value-chain support for portfolio companies through to IPO and exit.

Differentiator

Problem solved

Functional benefit

Products and services

  • TF Capital Early-Stage Biotech Venture Fund Dual-currency venture capital fund providing capital and full value-chain strategic support to early-stage biotech and pharmaceutical companies in China. Available to limited partners (institutional investors) as a committed-capital fund vehicle; deployed into portfolio companies as venture financing. Manages approximately $1B AUM and has invested in 100+ companies with 20+ IPOs achieved.

Quantifiable outcome

  • $2.8B+ in upfronts generated from 25 license-out deals across 14 companies in 5 consecutive years with MNCs
  • +5 more outcomes

Companies that use TF Capital

Customer profile

Named customers9 records

Segments2 records

Ideal customer profiles2 records

TF Capital technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

TF Capital partnerships and signals

Strategic signal

Scale indicators7 records

Recent moves5 records

Expansion highlights4 records

TF Capital competitors and assessment

Company assessment

Direct peers

  • ARCH Venture Partners: US-based early-stage biotech VC with a long track record of founding and exiting life sciences companies. Comparable in early-stage biotech sourcing and university/founder-relationship-driven model.
  • Loyal Valley Capital: China-focused asset manager with a dedicated biotech/healthcare investment platform and active license-out pipeline. Directly comparable in mandate, scale and China healthcare focus.
  • Qiming Venture Partners: Leading Shanghai-based VC with deep healthcare and biotech franchise. Co-led Vivatides' $54M Series A in which TF Capital participated, indicating directly overlapping deal flow and LP/market positioning.
  • Highlight Capital: Healthcare and biotech-dedicated China investor that participated in Vivatides' Series A alongside TF Capital, signaling directly overlapping deal sourcing and similar China biotech VC mandate.
  • OrbiMed: Global healthcare-dedicated investment firm with early-stage biotech activity, including exposure to China. Closely comparable in early-stage biotech focus and pharma partnership-driven exit model.
  • Legend Capital: Established China-focused VC with significant biotech investments; TF Capital partner Wei Cheng previously held senior roles at affiliated Tsinghua Holdings Capital/LegendStar, indicating a closely comparable franchise with overlapping networks.
  • Apricot Capital: China healthcare/biotech-focused investor and existing backer of Vivatides Therapeutics alongside TF Capital. Directly comparable as a co-investor in the same early-stage China biotech rounds.
  • Atlas Venture: US-based early-stage biotech-focused VC that builds companies from inception with a strong pharma partnership exit model. Comparable in biotech-only mandate and pharma BD-driven value creation.

Broad incumbents

  • Hillhouse Capital: Major China-rooted investment platform with material healthcare/biotech exposure across public and private markets. Comparable as a scaled incumbent in China biotech investing, though much broader in mandate.
  • HongShan (formerly Sequoia China): One of the largest China-focused VCs with active healthcare/biotech investing and global exit capabilities. Comparable incumbent competitor for biotech founders, though broader in sector coverage.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

TF Capital compliance and trust

Trust signal

Compliance1 record

TF Capital financial estimates

Financial estimate

Revenue estimate

Valuation estimate

TF Capital leadership team

Management profile

Number of profiles

Profiles2 records

TF Capital funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

TF Capital M&A and investment

M&A and investment

M&A

Investments61 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TF Capital

What does TF Capital do?

TF Capital is a Shanghai-based dual-currency venture capital firm that invests in early-stage innovative biotech and pharmaceutical companies in China. It provides capital and full value-chain strategic support to portfolio companies from inception through IPO, leveraging proprietary deal sourcing and deep biopharmaceutical networks. The firm has built a portfolio of 100+ companies and generated over $2.8B in upfront payments from license-out deals with multinational corporations.

Is TF Capital a public or private company?

TF Capital is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was TF Capital founded?

TF Capital was founded in 2014. It employs 11 to 50 people.

Where is TF Capital based?

TF Capital is headquartered in Shanghai, China, in the Asia region.

How does TF Capital make money?

One revenue line is on record: investment Returns and Management Fees.

Who are TF Capital's main competitors?

Direct peers on record are ARCH Venture Partners, Loyal Valley Capital, Qiming Venture Partners, Highlight Capital, OrbiMed, Legend Capital, Apricot Capital and Atlas Venture. Broad incumbents are Hillhouse Capital and HongShan (formerly Sequoia China).

Does TF Capital have an API?

No public API is recorded for TF Capital.

What industry is TF Capital in?

TF Capital's product category is Venture Capital — Early-Stage Biotech. Its primary akta.pro industry code is FSANAHAN, Corporate Strategic Real Assets & Infrastructure Venture Investing. Its NAICS code is 523 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pedaily明慧医药完成1.31亿美元Pre-IPO轮融资,奥博资本领投Minghui Pharmaceutical announced the completion of a $131 million Pre-IPO financing round led by OrbiMed, with Qiming Venture Partners co-leading and participation from TF Capital, BioTrack Capital, 5Y Capital, New Day Fund, and Wider Link Enterprise Investment Limited. Representatives from OrbiMed and Qiming Venture Partners will join the company's board of directors. The funding will accelerate the advancement of the company's core clinical-stage programs, including PD-1/VEGF bispecific antibodies and their ADCs for combination therapy, as well as support the commercialization preparation of topical JAK inhibitors in China.PR NewswireAskGene Limited Announces Completion of USD 20 Million Series A Financing Led by Qiming Venture Partners and TF CapitalAskGene Limited announced the completion of a USD 20 million Series A financing round led by Qiming Venture Partners and TF Capital. The company intends to use the proceeds to advance its SmartKine® cytokine prodrug platform and its clinical pipeline, including programs ASKB589 and ASKG712. This funding supports AskGene's efforts to develop next-generation immunotherapies for cancer and autoimmune diseases.Ebrun海思盖德完成1亿人民币Pre-A轮融资Haisegaide, a developer of high-end implantable drug and device products for ophthalmic diseases, completed a 100 million RMB Pre-A financing round. The investment was led by Boyuan Capital with participation from TF Capital and Taiyu Investment. These funds are intended to support the company's research and production efforts in the medical health sector.PR NewswireCBMG Holdings Completes $120 Million in Series A Funding, Accelerating Development of CAR-T Therapy Pipelines and R&D for Innovative Solid Tumor TherapiesCBMG Holdings, a Cayman Island biopharmaceutical company developing cellular immunotherapies for cancer and degenerative diseases, announced the closing of a $120 million Series A funding round led by AstraZeneca-CICC Fund, Sequoia Capital China, and Yunfeng Capital, with participation from existing investors including GIC, TF Capital, Novartis, and Sailing Capital. The capital will accelerate development of the company's immune-oncology platform, including CAR-T therapies C-CAR039 for relapsed or refractory non-Hodgkin lymphoma and C-CAR088 for multiple myeloma, as well as armored CAR-T and tumor-infiltrating lymphocyte therapies targeting solid tumors, and its stem cell platform including AlloJoin for knee osteoarthritis. The FDA previously granted Orphan Drug Designation to C-CAR039 for the treatment of Follicular Lymphoma, and the company successfully completed its privatization in February 2021 following its listing on NASDAQ.China Money NetworkChinese Medical Device Firm Hanyu Medical Secures $72M Series D RoundHanyu Medical, a Chinese high-end cardiac device company, completed a RMB500 million (US$72.05 million) Series D financing round. The round was co-led by Highlight Capital and CITIC Private Equity Funds.PR NewswireAntengene Corporation lève 120 millions USD en financement de série BAntengene Corporation, a clinical-stage oncology biopharma company based in China, has completed a $120 million Series B financing round co-led by Boyu Capital and FountainVest, with participation from Celgene Corporation, WuXi AppTec, Taikang, and previous investors Qiming Venture Partners and TF Capital. The funding will support the development of its lead drug programs ATG-008 and ATG-010 (selinexor), expand its pipeline through internal R&D and external partnerships, and prepare for commercial launch of advanced-stage candidates. The company is constructing a 169,984 square-foot manufacturing facility in Shaoxing, China, compliant with GMP standards for clinical and commercial drug supply.FinSMEsGeneQuantum Raises RMB40M in Series A FinancingGeneQuantum Healthcare, a Suzhou-based bio-therapeutics firm, raised RMB40m ($5.8m) in a Series A led by Oriza Seed Venture Capital with TF Capital. The funds will support advancing its ADC candidates toward IND filing in the US and China, and expanding its pipeline.PR NewswireGeneQuantum Closes RMB40 Million Series A FinancingGeneQuantum Healthcare (Suzhou) Co., Ltd. completed a RMB40 million (approximately $5.8 million) Series A financing round led by Oriza Seed Venture Capital, with participation from TF Capital. The funding will support the development of the company's next-generation antibody-drug conjugates toward Investigational New Drug applications in both the US and China, while also expanding its product pipeline. GeneQuantum was founded in 2013 at Suzhou Industrial Park and operates a bio-conjugation technology platform focused on innovative anti-tumor therapeutics.